MiMedx Board Member Grows Stake to 212,000 Shares in Latest Stock Award
Rhea-AI Filing Summary
MiMedx Group director James L. Bierman acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing his total direct holdings to 212,771 shares.
The acquisition represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. The awarded shares will vest upon the earlier of:
- 12 months from grant date
- The next annual meeting of shareholders
The Form 4 filing was signed by William F. Hulse as attorney-in-fact for Bierman on June 23, 2025. This transaction demonstrates continued alignment of director interests with shareholders through equity-based compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 28,609 shares
Net Buy
1 txn
Insider
BIERMAN JAMES L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 28,609 | $6.47 | $185K |
Holdings After Transaction:
Common Stock — 212,771 shares (Direct)
Footnotes (1)
- F1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is the vesting period for MDXG's director stock grants in 2025?
The restricted stock grant for MDXG's non-employee directors vests upon the earlier of 12 months or the next annual meeting of shareholders. This grant was made under Rule 16b-3 exemption.